Direct Oral Anticoagulant Drugs in Dental Clinical Practice

1. Schulman S. Advantages and limitations of the new anticoagulants. J Int Med 2014; 275(1): 1-11.10.1111/joim.1213824112453Search in Google Scholar

2. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. J Thromb Haemost. 2011;105(5):908-19.10.1160/TH11-02-008921431243Search in Google Scholar

3. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.10.1056/NEJMoa090556119717844Search in Google Scholar

4. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fi brillation. N Engl J Med 2011; 365:883-891.10.1056/NEJMoa100963821830957Search in Google Scholar

5. Cohen AT, Spiro TE, Buller HR, et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368:513-523.10.1056/NEJMoa111109623388003Search in Google Scholar

6. Hirsh J, O'Donnell M and Weitz JY.New anticoagulants. Blood 2005; 105:453-463.10.1182/blood-2003-12-419515191946Search in Google Scholar

7. Pradaxa 150 mg cps dur. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdfSearch in Google Scholar

8. Xarelto 10 mg tbl flm. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdfSearch in Google Scholar

9. Eliquis 5 mg tbl flm. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdfSearch in Google Scholar

10. Geerts B. The Role of Warfarin in the Era of New Oral Anticoagulants. The 9th International Winter Arrhythmia School, Collingwood, February 12, 2012. Available at: www.winterarrhythmia.com, [cit.2015-04-07].Search in Google Scholar

11. Raval AN, Cigarroa JE, Chung MK. Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting. A Scientific Statement From the American Heart Association. Circulation. 2017;135(10) : e604-e633. DOI: 10.1161/CIR. 0000000000000477. Available at: http://circ.ahajournals.org/content/135/10/e604.long, [cit.2015-04-07].10.1161/CIR.000000000000049328264900Search in Google Scholar

12. Connolly G, Spyropoulos AC. Practical issues, limitations, and periprocedural management of the NOAC’s. J Thromb Thrombolysis 2013; 36:212-222.10.1007/s11239-013-0911-223532364Search in Google Scholar

13. vanRyn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103 (6):1116-1127.10.1160/TH09-11-075820352166Search in Google Scholar

14. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery? Blood 2012; 120 (15):2954-2962.Search in Google Scholar

15. Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Clev Clin J Med 2013; 80 (7):443-451.10.3949/ccjm.80a.1302523821689Search in Google Scholar

16. UC Davis Health System Anticoagulation Services Recommendations for anticoagulation management before and after dental procedures, Approved by UCDHS Pharmacy and Therapeutics Committee 6/2015. Available at: https://www.ucdmc.ucdavis.edu/anticoag/pdf/AnticoagDentalProcedure.pdf, [cit.2015-04-07].Search in Google Scholar

17. Ballantyne S. Guidenline for managing patients on Rivaroxaban (XareltoR), 2013, Available at: http://www.health.qld.gov.au./qhcss/mapsu/documents/dabigatran_info.pdf, [cit.2015-04-07].Search in Google Scholar

18. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e326S-50S.10.1378/chest.141.4.1129bSearch in Google Scholar

19. Mingaro-De-Leon A, Chaveli-Lopez B. Alternative to oral dicoumarin anticoagulants: Consideration in dental care. Journal of clinical and experimental dentistry, 2013; 5(5):273-278.10.4317/jced.51226389226024455094Search in Google Scholar

20. Randall C. MWMIC Medicines FAQ. New oral anticoagulants (NOACs) and management of dental pa - tients - Dabigatran, rivaroxaban and apixaban. Dental Clinical Guidance. May 2013, Updated Nov 2013. Available at: www.eryldc.co.uk, [cit.2015-04-07].Search in Google Scholar

21. Wahl, MJ. Myths of dental surgery in patients receiving anticoagulant therapy. J Am Dent Assoc 2000; 131:77-81.10.14219/jada.archive.2000.002410649877Search in Google Scholar

22. Israels S, Schwetz N, Boyar R, et al. Bleeding Disorders: Characterization, Dental Considerations and Management. Can Dent Assoc 2006; 72(9):827.Search in Google Scholar